Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of adebrelimab + bevacizumab + GEMOX in unresectable biliary tract carcinoma
ChiCTR2400083844Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, bevacizumab, gemcitabine and oxaliplatin in biliary cancer, sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
adebrelimabbevacizumabgemcitabineoxaliplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400083844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083844.